Rexahn Pharmaceuticals to Present at Needham & Company’s 10th Annual Healthcare Conference

ROCKVILLE, Md.--(BUSINESS WIRE)-- Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will present at Needham & Company’s 10th Annual Healthcare Conference on Wednesday, April 6, 2011, at 2:40 p.m. EDT in New York City.

Rexahn’s President and Chief Operating Officer, Rick Soni, and Chief Financial Officer, Ted Jeong, will provide a strategic business overview of the Company, including a discussion of its R&D pipeline. Presentation materials from the conference will be available in the Investor Relations section of the Company’s website, www.rexahn.com.

About Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to developing and commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin®, Serdaxin®, and Zoraxel™ - all potential best in class therapeutics - and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders. Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms. For more information, please visit www.rexahn.com.



CONTACT:

Rexahn Pharmaceuticals, Inc.
Investors
Stern Investor Relations, Inc.
Stephanie Ascher, 212-362-1200
[email protected]
or
Media
Base Pair Communications
Constantine Theodoropulos, 617-401-3116
[email protected]

KEYWORDS:   United States  North America  Maryland  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."